CN115541755B - Quality control method of nifuratel tablet - Google Patents

Quality control method of nifuratel tablet Download PDF

Info

Publication number
CN115541755B
CN115541755B CN202211218858.6A CN202211218858A CN115541755B CN 115541755 B CN115541755 B CN 115541755B CN 202211218858 A CN202211218858 A CN 202211218858A CN 115541755 B CN115541755 B CN 115541755B
Authority
CN
China
Prior art keywords
impurity
nifuratel
solution
liquid chromatography
high performance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211218858.6A
Other languages
Chinese (zh)
Other versions
CN115541755A (en
Inventor
陈妙秀
蓝永锋
李慧敏
梁嘉琪
吴儒超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUANGDONG HENGJIAN PHARMACEUTICAL CO Ltd
Original Assignee
GUANGDONG HENGJIAN PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGDONG HENGJIAN PHARMACEUTICAL CO Ltd filed Critical GUANGDONG HENGJIAN PHARMACEUTICAL CO Ltd
Priority to CN202211218858.6A priority Critical patent/CN115541755B/en
Publication of CN115541755A publication Critical patent/CN115541755A/en
Application granted granted Critical
Publication of CN115541755B publication Critical patent/CN115541755B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N30/06Preparation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/26Conditioning of the fluid carrier; Flow patterns
    • G01N30/28Control of physical parameters of the fluid carrier
    • G01N30/34Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/86Signal analysis
    • G01N30/8675Evaluation, i.e. decoding of the signal into analytical information
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N2030/042Standards
    • G01N2030/047Standards external
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Library & Information Science (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

The invention belongs to the technical field of medicine quality control, and particularly relates to a quality control method of nifuratel tablets, which adopts high performance liquid chromatography, and the conditions are set as follows: octadecyl bonded silica gel chromatographic column, column temperature 30deg.C, sample injection amount 10μl, flow rate 1.0ml/min, detection wavelength 210nm, and eluting with organic phase-water phase as mobile phase. The high performance liquid chromatography provided by the invention has good repeatability, stability and instrument and chromatographic condition adaptability, the detection sensitivity and separation degree of six impurities or components such as oxidized impurity II, oxidized impurity III, impurity A, impurity B, impurity C and nifuratel in the nifuratel tablet are high, the signal to noise ratio (S/N) is more than 10.0, the RSD is less than 10%, the measurement result is ensured to have good stability, the detection durability of the nifuratel tablet can be obviously improved, and the method is simple, quick and sensitive, and the impurity level in the product can be effectively controlled.

Description

Quality control method of nifuratel tablet
Technical Field
The invention belongs to the technical field of medicine quality control, and particularly relates to a quality control method of nifuratel tablets.
Technical Field
Nifuratel is a broad-spectrum antibiotic, clinically used as a gynecological antibacterial drug for treating bacterial vaginitis. The structural formula is as follows:
the synthetic route of the nifuratel which is mature in industry at present is shown as follows:
intermediate IP01 is prepared from starting material SM01 (impurity C) under the condition of sulfuric acid, intermediate IP02 (impurity B) is prepared from starting material SM02 under the condition of dimethyl carbonate, and then intermediate IP01 and intermediate IP02 are condensed under the condition of sulfuric acid to prepare nifuratel. However, due to the oxidizing nature of sulfuric acid, the thioethers in nifuratel may be further oxidized to form oxidized impurities II and III. The structural formula is as follows:
in the preparation of nifuratel from starting materials, multi-step reactions are involved, and there is a risk of residual starting materials and intermediates in the final nifuratel product, and at the same time, there is a risk of increased levels of oxidized impurities during the preparation and storage of nifuratel tablets. The above impurity information is as follows:
the polarity difference of the impurities is large, at present, few reports are about a method for simultaneously detecting various impurities in a nifuratel drug, for example, chinese patent CN201910052941.2 discloses an impurity control method for nifuratel vaginal tablets, which detects nifuratel, 5-nitrofurfural diacetate, 5-nifuratel pyridazine, nifuratel oxidized impurities and photodegradation impurities contained in nifuratel vaginal tablets by high performance liquid chromatography, but the separation degree of the substances obtained by the method is low, cross coincidence exists between impurity peaks, and meanwhile, the specific structures of the oxidized and degraded impurities and photodegradation impurities are not definitely detected by the method, so that better quality control is difficult to obtain; sun Guoxiang et al, HPLC content determination of 4 intermediates in nifuratel preparation process, including 2- (methylthiomethyl) -oxirane, 3-methylthio-2-hydroxy-propylhydrazine, N-amino-5-methylthiomethyl-2-oxazolidinone, 5-nitrofurfural, but this document mainly aims to solve the problem of product purity control in nifuratel synthesis process, it is difficult to perform more comprehensive quality control on nifuratel drug storage process (Sun Guoxiang, deng Haiying, lifei. HPLC method to determine the content of 4 intermediates of nifuratel and related substances [ J ]. J.North-West pharmaceutical J, 2011,26 (005): 334-337); yinghua the preparation and quality control of nifuratel vaginal tablet are studied, and high performance liquid chromatography is adopted to detect nifuratel and 5-nitrofurfural diacetate in nifuratel vaginal tablet (Yinghua. Preparation and quality control of nifuratel vaginal tablet [ J ]. Chinese medical journal, 2016,8:852-853,857), but since nifuratel tablet can produce degradation, oxidation and the like in the preparation and storage process, the impurity content is more, the literature only detects single impurity in the preparation process, and the comprehensive quality control of nifuratel drug is difficult, therefore, a simple, rapid and sensitive detection method is developed, and a plurality of impurities in nifuratel drug are detected simultaneously, thus providing important basis for the quality control of nifuratel drug.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a quality control method of nifuratel tablets, and the detection method has the advantages of simple and quick sample treatment, sensitivity, easy operation and good method adaptability, can effectively detect a plurality of impurities in nifuratel tablets at the same time, and has excellent separation and detection effects.
In a first aspect, the invention provides a quality control method of nifuratel tablets, wherein the quality control method is high performance liquid chromatography.
Further, the conditions of the high performance liquid chromatography adopted by the invention are as follows:
chromatographic column: adopting octadecyl bonded silica gel chromatographic column;
column temperature: 25-35 ℃;
flow rate: 0.8 ml/min-1.2 ml/min;
sample injection amount: 5-20 mu l;
detection wavelength: 205nm to 215nm;
mobile phase: mixing organic phase and water phase;
the mobile phase programming is shown in table 1:
table 1: mobile phase procedure
Time (min) Aqueous phase (%) Organic phase (%)
0 90~70 10~30
2 90~70 10~30
13 50~30 50~70
13.1 90~70 10~30
20 90~70 10~30
In a second aspect, the invention provides specific steps of a quality control method of the nifuratel tablet:
s1, preparing a blank solution: acetonitrile and water are mixed according to the volume ratio of 40:60, uniformly mixing to prepare a blank solution;
s2, reference substance stock solution: precisely weighing oxidized impurity II, oxidized impurity III, impurity A, impurity B, impurity C and nifuratel reference substances, respectively placing into a measuring flask, dissolving and diluting with acetonitrile to scale, and shaking uniformly to obtain oxidized impurity II, oxidized impurity III, impurity A, impurity B, impurity C and nifuratel reference substance stock solution;
s3, reference substance solution: precisely measuring oxidized impurities II, oxidized impurities III, impurities A, impurities B, impurities C and nifuratel reference substance stock solution in the step S2, placing the stock solution in the same measuring flask, diluting to scale with blank solution, shaking uniformly to obtain reference substance solution, and sampling under the set high performance liquid chromatography condition to complete analysis;
s4, sample solution: grinding nifuratel tablet into powder, placing into a measuring flask, adding a small amount of acetonitrile, performing ultrasonic dissolution, diluting with acetonitrile to scale, filtering, placing the filtrate into the measuring flask, diluting with blank solution to scale, shaking to obtain sample solution, and performing sample injection under the set high performance liquid chromatography condition to complete analysis.
Preparing a positioning solution, a sensitivity solution and a separation degree solution according to the experimental conditions and the method respectively:
(1) Positioning solution: respectively measuring the reference stock solutions of the oxidized impurities II, the oxidized impurities III, the impurities A, the impurities B and the impurities C in the step S2, respectively placing the reference stock solutions in a measuring flask, diluting the reference stock solutions to scale with acetonitrile, and shaking the reference stock solutions uniformly to obtain positioning solutions of the oxidized impurities II, the oxidized impurities III, the impurities A, the impurities B and the impurities C;
(2) Sensitivity solution: precisely measuring the reference substance solution in the step S3, placing the reference substance solution in a measuring flask, diluting the reference substance solution to a scale with a blank solution, and shaking the solution uniformly to obtain a sensitivity solution;
(3) Degree of separation solution: and (3) placing nifuratel powder in the step (S4) in a measuring flask, adding a small amount of acetonitrile, carrying out ultrasonic dissolution, diluting to a scale with acetonitrile, filtering, placing the subsequent filtrate in the measuring flask, precisely measuring the reference substance positioning solutions of oxidized impurities II, oxidized impurities III, impurities A, impurities B and impurities C, placing the reference substance positioning solutions in the 10ml measuring flask, fully mixing, diluting to the scale with a blank solution, and shaking uniformly to obtain a separation degree solution (100% of the solution for adding the standard sample).
The molecular structural formulas of the oxidized impurities II, III, A, B and C are as follows:
oxidizing impurity II:
oxidizing impurity III:
impurity A: 5-Nifuropyridazine (Process impurity in preparation)
Impurity B: 2-amino-5-methylthiomethyl-2-oxazolidinone (intermediate in the preparation process)
Impurity C: 5-Nitrofurfural diacetate (starting Material impurity during preparation)
The quality control method of the nifuratel tablet provided by the invention is not limited to the quality control of the nifuratel tablet, and can also comprise other dosage forms, such as capsules, pills and the like.
Compared with the prior art, the invention has the following beneficial effects:
the high performance liquid chromatography provided by the invention has good repeatability, good stability of the solution of the test sample, good adaptability of instruments and chromatographic conditions, high detection sensitivity and separation degree of six impurities or components such as oxidized impurity II, oxidized impurity III, impurity A, impurity B, impurity C, nifuratel and the like in the nifuratel tablet, and a signal to noise ratio (S/N) of more than 10.0, RSD of less than 10%, good stability of a measurement result, and capability of greatly improving the detection durability of the nifuratel tablet, and the quality control method of the nifuratel tablet is successfully developed.
Drawings
FIG. 1 is a chromatogram of a hollow white solution of example 1.
FIG. 2 is a chromatogram of the control solution in example 1.
FIG. 3 is a chromatogram of the sensitivity solution in example 1.
FIG. 4 is a chromatogram of the sample solution in example 1.
FIG. 5 is a chromatogram of the resolution solution of example 1.
FIG. 6 is a chromatogram of the resolution solution of example 2.
FIG. 7 is a chromatogram of the resolution solution of example 3.
FIG. 8 is a chromatogram of the resolution solution of example 6.
FIG. 9 is a chromatogram of the resolution solution of example 7.
FIG. 10 is a chromatogram of the resolution solution of example 8.
FIG. 11 is a chromatogram of the resolution solution of example 9.
FIG. 12 is a chromatogram of the resolution solution of example 10.
FIG. 13 is a chromatogram of the resolution solution of example 11.
FIG. 14 is a chromatogram of the resolution solution of example 12.
FIG. 15 is a chromatogram of the resolution solution of example 13.
Detailed Description
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The present invention will be further described in detail with reference to the following embodiments, in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the description is only illustrative and is not intended to limit the scope of the invention. In addition, in the following description, descriptions of well-known structures and techniques are omitted so as not to unnecessarily obscure the present invention.
All other embodiments obtained by persons of ordinary skill in the art without making any creative effort based on the embodiments of the present invention are within the protection scope of the present invention, and the following embodiments are further described for the present invention, but are not meant to limit the protection scope of the present invention.
The specific sources and types of partial raw materials and instruments used in the invention are shown in table 1:
example 1
The chromatographic conditions set in the high performance liquid chromatography method are as follows:
instrument: thermo U3000 high performance liquid chromatograph;
chromatographic column: octadecyl bonded silica gel column (specification: 150 x 4.6mm,5 um);
column temperature: 30 ℃;
sample injection amount: 10 μl;
flow rate: 1.0ml/min;
detection wavelength: 210nm;
mobile phase: the organic phase is acetonitrile, the aqueous phase is ultrapure water, and the specific table 2 shows;
table 2:
time (min) Ultrapure water (%) Acetonitrile (%)
0 80 20
2 80 20
13 40 60
13.1 80 20
20 80 20
The specific experimental steps are as follows:
s1, blank solution: acetonitrile-water (volume ratio 40:60);
s2, reference substance stock solution: precisely weighing 20mg of oxidized impurity II, oxidized impurity III, impurity A, impurity B, impurity C and nifuratel reference substance respectively, putting into 100ml measuring flask, respectively, dissolving and diluting with acetonitrile to scale, shaking uniformly to obtain oxidized impurity II, oxidized impurity III, impurity A, impurity B, impurity C and nifuratel reference substance stock solution with concentration of 200 mug/ml;
s3, reference substance solution: precisely measuring 1.0ml of each of the oxidized impurity II, oxidized impurity III, impurity A, impurity B, impurity C and nifuratel reference substance stock solution in the step S2, placing the stock solutions in a same 100ml measuring flask, diluting to a scale with a blank solution, and shaking uniformly to obtain a reference substance solution with the concentration of 2 mug/ml;
s4, sample solution: taking 20 nifuratel tablets (200 mg in specification), grinding into powder, weighing 1000mg of powder (400 mg containing nifuratel), placing into a 100ml measuring flask, adding a small amount of acetonitrile, carrying out ultrasonic treatment to dissolve, and diluting with acetonitrile to a scale. Filtering, collecting 2.5ml of the filtrate, placing in a 10ml measuring flask, diluting to scale with blank solution, and shaking to obtain sample solution with concentration of 1 mg/ml.
Preparing blank solution, positioning solution, sensitivity solution and separation degree solution according to the experimental conditions and methods:
(1) Positioning solution: respectively measuring 1.0ml of each of the reference stock solutions of the oxidized impurities II, the oxidized impurities III, the impurities A, the impurities B and the impurities C in the step S2, respectively placing in a 10ml measuring flask, diluting to a scale with acetonitrile, and shaking uniformly to obtain positioning solutions of the oxidized impurities II, the oxidized impurities III, the impurities A, the impurities B and the impurities C with the concentration of 20 mug/ml respectively;
(2) Sensitivity solution: precisely measuring 2.5ml of the reference substance solution in the step S3, placing in a 10ml measuring flask, diluting to a scale with a blank solution, and shaking uniformly to obtain a sensitivity solution with the concentration of 0.5 mug/ml;
(3) Degree of separation solution: taking about 1000mg (about 400mg containing nifuratel) of the powder in the step S4, placing the powder in a 100ml measuring flask, adding a small amount of acetonitrile, carrying out ultrasonic treatment to dissolve, diluting with acetonitrile to a scale, filtering, taking 2.5ml of the subsequent filtrate, placing the filtrate in a 10ml measuring flask, precisely measuring 1ml of each of oxidized impurity II, oxidized impurity III, impurity A, impurity B and impurity C reference substance positioning solutions, placing the obtained solution in the 10ml measuring flask, mixing, diluting with a blank solution to the scale, shaking uniformly, and taking the obtained solution as a separation degree solution (100% of the standard sample solution).
The prepared blank solution, reference solution, sample solution, sensitivity solution and separation degree solution were subjected to high performance liquid chromatography under the above chromatographic conditions, and chromatograms were recorded, and the results are shown in fig. 1 (blank solution), fig. 2 (reference solution), fig. 3 (sensitivity solution), fig. 4 (sample solution) and fig. 5 (separation degree solution), and the minimum separation degree of the separation degree solution obtained by using the high performance liquid chromatography conditions of this example 1 was 4.02, and the minimum signal to noise ratio of the sensitivity solution was 58.0.
Example 2
The chromatographic conditions set in the high performance liquid chromatography method are as follows:
instrument: thermo U3000 high performance liquid chromatograph;
chromatographic column: octadecyl bonded silica gel chromatographic column (150 x 4.6mm,5 um)
Column temperature: 30 DEG C
Sample injection amount: 10 μl of
Flow rate: 1.0ml/min
Detection wavelength: 210nm of
Mobile phase: the organic phase is acetonitrile, the aqueous phase is ultrapure water, and the specific table 3 shows;
table 3:
time (min) Ultrapure water (%) Acetonitrile (%)
0 70 30
2 70 30
13 30 70
13.1 70 30
20 70 30
The specific experimental procedure is the same as in example 1, the blank solution and the separation degree solution are respectively taken, high performance liquid chromatography analysis is carried out under the chromatographic conditions, the chromatogram is recorded, the separation degree solution result is shown in fig. 6, the minimum separation degree in fig. 6 is 2.49, and the separation degree meets the requirement.
Example 3
The chromatographic conditions set in the high performance liquid chromatography method are as follows:
instrument: thermo U3000 high performance liquid chromatograph;
chromatographic column: octadecyl bonded silica gel column (specification: 150 x 4.6mm,5 um);
column temperature: 30 ℃;
sample injection amount: 10 μl;
flow rate: 1.0ml/min;
detection wavelength: 210nm;
mobile phase: the organic phase is acetonitrile, the aqueous phase is ultrapure water, and the specific table 4 shows;
table 4:
time (min) Ultrapure water (%) Acetonitrile (%)
0 90 10
2 90 10
13 50 50
13.1 90 10
20 90 10
The experimental procedure is the same as in example 1, the blank solution and the separation degree solution are respectively taken, high performance liquid chromatography analysis is carried out under the chromatographic conditions, the chromatogram is recorded, the separation degree solution result is shown in fig. 7, the minimum separation degree in fig. 7 is 3.72, and the separation degree meets the requirement.
Examples 1 to 3 are optimized processes of elution systems in the high performance liquid chromatography method, separation can be achieved by 3 elution systems, the retention time of each impurity is greatly influenced by different elution systems, the influence of the baseline on the impurities in example 1 is smaller than that in examples 2 and 3, and finally the high performance liquid chromatography method in example 1 is preferred.
Example 4
The chromatographic conditions set in the high performance liquid chromatography method were the same as in example 1;
the experimental steps are as follows:
the preparation methods of the blank solution, the reference solution, the test sample solution and the separation degree solution (100% of the labeled test sample solution) are the same as those of example 1, wherein 6 parts of the separation degree solution (100% of the labeled test sample solution) are prepared in parallel to be used as 1-6 parts of the 100% of the labeled solution.
Taking blank solution, reference solution, test solution and 100% standard test solution 1-6 respectively, performing high performance liquid chromatography under the above chromatographic conditions, recording the chromatogram, and the results are shown in Table 5 below;
table 5: yield results of addition of the mark
As shown in Table 5, the recovery rate of the 100% standard solution of 6 parts was 93.6% -106.2%, the recovery rate was 90% -108%, and the RSD (n=6) was 1.6% -4.2% < 10.0%, which meets the requirements.
Example 5
The chromatographic conditions set in the high performance liquid chromatography method were the same as in example 1;
the experimental steps are as follows:
the preparation method of the blank solution and the sensitivity solution is the same as that of example 1, and high performance liquid chromatography analysis is carried out under the chromatography condition, wherein the sensitivity solution is injected in parallel for 6 times, and the result is shown in the following table 6;
table 6: sensitivity results
As shown in Table 6, the peak area RSD (n=6) of the sensitive solution is 0.5% -3.8% < 10.0%, and the signal to noise ratio (S/N) is 58.0-176.5 >10.0, which indicates that the high performance liquid chromatography p-nifuratel tablet has good detection precision and sensitivity for each impurity.
Example 6
The column temperature was set to 25 ℃ in the chromatographic conditions set in the high performance liquid chromatography method, and other chromatographic conditions were the same as in example 1;
the experimental steps are as follows:
the preparation method of the sensitivity solution and the separation degree solution is the same as that of example 1, high performance liquid chromatography analysis is carried out under the chromatographic conditions, and a chromatogram is recorded, and the result is shown in fig. 8;
as can be seen from the chromatogram in fig. 8, the minimum separation of the separation solution obtained by setting the column temperature to 25 ℃ in this example was 4.08, and the minimum signal-to-noise ratio of the sensitivity solution was 34.9, compared with the column temperature set to 30 ℃ (example 1).
Example 7
The column temperature was set to 35 ℃ in the chromatographic conditions set in the high performance liquid chromatography method, and other chromatographic conditions were the same as in example 1;
the experimental steps are as follows:
the preparation method of the sensitivity solution and the separation degree solution is the same as that of example 1, high performance liquid chromatography analysis is carried out under the chromatographic conditions, and a chromatogram is recorded, and the result is shown in fig. 9;
as can be seen from the results of fig. 9, the minimum separation of the separation solution obtained by setting the column temperature to 35 c in this example was 3.93 and the minimum signal-to-noise ratio of the sensitivity solution was 44.6, compared to the column temperature set to 30 c (example 1).
Example 8
The flow rate was set to 0.8ml/min in the chromatographic conditions set in the high performance liquid chromatography method, and the other chromatographic conditions were the same as in example 1;
the experimental steps are as follows:
the preparation method of the sensitivity solution and the separation degree solution is the same as that of example 1, high performance liquid chromatography analysis is carried out under the chromatographic conditions, and a chromatogram is recorded, and the result is shown in fig. 10;
as can be seen from the results of FIG. 10, the minimum separation of the separation solution obtained by setting the flow rate to 0.8ml/min in this example was 4.01 and the minimum signal-to-noise ratio of the sensitivity solution was 38.7, compared to the case where the flow rate was set to 1.0ml/min (example 1).
Example 9
The flow rate was set to 1.2ml/min in the chromatographic conditions set in the high performance liquid chromatography method, and the other chromatographic conditions were the same as in example 1;
the experimental steps are as follows:
the preparation method of the sensitivity solution and the resolution solution is the same as that of example 1, high performance liquid chromatography analysis is carried out under the chromatographic conditions, and a chromatogram is recorded, and the result is shown in fig. 11;
as can be seen from the results of FIG. 11, the minimum separation of the separation solution obtained by setting the flow rate to 1.2ml/min in this example was 4.00 and the minimum signal-to-noise ratio of the sensitivity solution was 36.4, compared to the case where the flow rate was set to 1.0ml/min (example 1).
Example 10
The sample injection amount was set to 5. Mu.l in the chromatographic conditions set in the high performance liquid chromatography method, and the other chromatographic conditions were the same as in example 1;
the experimental steps are as follows:
the preparation method of the sensitivity solution and the separation degree solution is the same as that of example 1, high performance liquid chromatography analysis is carried out under the chromatographic conditions, and a chromatogram is recorded, and the result is shown in fig. 12;
as can be seen from the results of FIG. 12, the minimum separation of the separation solution obtained by setting the sample amount to 5. Mu.l in this example was 6.91 and the minimum signal to noise ratio of the sensitivity solution was 15.4, compared with the sample amount set to 10. Mu.l (example 1).
Example 11
The sample injection amount was set to 20. Mu.l in the chromatographic conditions set in the high performance liquid chromatography method, and the other chromatographic conditions were the same as in example 1;
the experimental steps are as follows:
the preparation method of the sensitivity solution and the separation degree solution is the same as that of example 1, high performance liquid chromatography analysis is carried out under the chromatographic conditions, and a chromatogram is recorded, and the result is shown in fig. 13;
as can be seen from the results of FIG. 13, the minimum separation of the separation solution obtained by setting the sample amount to 20. Mu.l in this example was 3.18 and the minimum signal to noise ratio of the sensitivity solution was 54.3, compared to the sample amount set to 10. Mu.l (example 1).
Example 12
The detection wavelength was set to 205nm in the chromatographic conditions set in the high performance liquid chromatography method, and the other chromatographic conditions were the same as in example 1;
the experimental steps are as follows:
the preparation method of the sensitivity solution and the separation degree solution is the same as that of example 1, high performance liquid chromatography analysis is carried out under the chromatographic conditions, and a chromatogram is recorded, and the result is shown in fig. 14;
as can be seen from the results of fig. 14, the minimum separation of the separation solution obtained by setting the detection wavelength to 205nm in this example was 4.08, and the minimum signal-to-noise ratio of the sensitivity solution was 42.0, compared to the case where the wavelength was set to 210nm (example 1).
Example 13
The detection wavelength was set to 215nm in the chromatographic conditions set in the high performance liquid chromatography method, and the other chromatographic conditions were the same as in example 1;
the experimental steps are as follows:
the preparation method of the sensitivity solution and the resolution solution is the same as that of example 1, high performance liquid chromatography analysis is carried out under the chromatographic conditions, and a chromatogram is recorded, and the result is shown in fig. 15;
as can be seen from the results of fig. 15, the minimum separation of the separation solution obtained by setting the detection wavelength to 215nm in this example was 4.09, and the minimum signal-to-noise ratio of the sensitivity solution was 35.5, compared to the detection wavelength set to 210nm (example 1).
Examples 6 to 13 are the investigation of chromatographic conditions in different durability ranges, the system applicability can meet the requirements, and the results of the examples are summarized in Table 7;
table 7: summary of results from different chromatographic conditions
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While still being apparent from variations or modifications that may be made by those skilled in the art are within the scope of the invention.

Claims (7)

1. The quality control method of nifuratel tablet is characterized in that the quality control method is high performance liquid chromatography, and the mobile phase program of the liquid chromatography is set as follows:
0min: 80-90% of water phase and 10-20% of organic phase;
2min: 80-90% of water phase and 10-20% of organic phase;
13min: 40-50% of water phase and 50-60% of organic phase;
13.1min: 80-90% of water phase and 10-20% of organic phase;
20min: 80-90% of water phase and 10-20% of organic phase;
the organic phase is acetonitrile;
the high performance liquid chromatography adopts octadecyl bonded silica gel chromatographic column;
the quality control process is that high performance liquid chromatography detects nifuratel and five impurity components therein simultaneously, the five impurity components include: the impurity A is 5-nifuradazine, the impurity B is 2-amino-5-methylthiomethyl-2-oxazolidone, and the impurity C is 5-nitrofurfural diacetate, oxidized impurity II and oxidized impurity III;
the structural formula of the oxidized impurity II is
The structural formula of the oxidized impurity III is
2. The quality control method of nifuratel tablet according to claim 1, characterized in that the column temperature of said high performance liquid chromatography is 25-35 ℃.
3. The quality control method of nifuratel tablet according to claim 1, characterized in that the flow rate of said high performance liquid chromatography is 0.8ml/min to 1.2ml/min.
4. The quality control method of nifuratel tablet according to claim 1, characterized in that the sample injection amount of the high performance liquid chromatography is 5-20 μl.
5. The quality control method of nifuratel tablet according to claim 1, characterized in that the detection wavelength of said high performance liquid chromatography is 205 nm-215 nm.
6. The quality control method of nifuratel tablet according to any one of claims 1 to 5, characterized by comprising the steps of:
s1, preparing a blank solution: acetonitrile and water are mixed according to the volume ratio of 40:60, uniformly mixing to prepare a blank solution;
s2, reference substance stock solution: precisely weighing oxidized impurity II, oxidized impurity III, impurity A, impurity B, impurity C and nifuratel reference substances, respectively placing into a measuring flask, dissolving and diluting with acetonitrile to scale, and shaking uniformly to obtain oxidized impurity II, oxidized impurity III, impurity A, impurity B, impurity C and nifuratel reference substance stock solution;
s3, reference substance solution: precisely measuring oxidized impurity II, oxidized impurity III, impurity A, impurity B, impurity C and nifuratel reference substance stock solution in the step S2, placing the stock solution in the same measuring flask, diluting to scale with blank solution, shaking uniformly to obtain reference substance solution, and injecting under the set high performance liquid chromatography condition;
s4, sample solution: grinding nifuratel tablet into powder, placing into a measuring flask, adding a small amount of acetonitrile, performing ultrasonic dissolution, diluting with acetonitrile to scale, filtering, placing the filtrate into the measuring flask, diluting with blank solution to scale, shaking to obtain sample solution, and performing sample injection under the set high performance liquid chromatography condition to complete analysis.
7. The method for quality control of nifuratel tablet according to claim 1, characterized in that said mobile phase procedure of liquid chromatography is set as:
0min: 80% of ultrapure water and 20% of acetonitrile;
2min: 80% of ultrapure water and 20% of acetonitrile;
13min: ultrapure water 40%, acetonitrile 60%;
13.1min: 80% of ultrapure water and 20% of acetonitrile;
20min: the ultrapure water was 80% and the acetonitrile was 20%.
CN202211218858.6A 2022-09-29 2022-09-29 Quality control method of nifuratel tablet Active CN115541755B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211218858.6A CN115541755B (en) 2022-09-29 2022-09-29 Quality control method of nifuratel tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211218858.6A CN115541755B (en) 2022-09-29 2022-09-29 Quality control method of nifuratel tablet

Publications (2)

Publication Number Publication Date
CN115541755A CN115541755A (en) 2022-12-30
CN115541755B true CN115541755B (en) 2023-10-27

Family

ID=84732503

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211218858.6A Active CN115541755B (en) 2022-09-29 2022-09-29 Quality control method of nifuratel tablet

Country Status (1)

Country Link
CN (1) CN115541755B (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101332192A (en) * 2008-02-28 2008-12-31 李国栋 Preparation of nifuratel and nysfungin vaginal soft capsules
CN102885793A (en) * 2012-10-15 2013-01-23 山东罗欣药业股份有限公司 Nifuratel compound tablet and preparation method thereof
CN109839456A (en) * 2019-01-21 2019-06-04 安徽省先锋制药有限公司 A kind of impurity control method of Nifuratel vaginal tablets
CN115032306A (en) * 2022-06-24 2022-09-09 广东恒健制药有限公司 Method for determining content of nifuratel in nifuratel tablets

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013115926A2 (en) * 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101332192A (en) * 2008-02-28 2008-12-31 李国栋 Preparation of nifuratel and nysfungin vaginal soft capsules
CN102885793A (en) * 2012-10-15 2013-01-23 山东罗欣药业股份有限公司 Nifuratel compound tablet and preparation method thereof
CN109839456A (en) * 2019-01-21 2019-06-04 安徽省先锋制药有限公司 A kind of impurity control method of Nifuratel vaginal tablets
CN115032306A (en) * 2022-06-24 2022-09-09 广东恒健制药有限公司 Method for determining content of nifuratel in nifuratel tablets

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Determination of Nifuratel in Human Plasma by HPLC and Study on Its Pharmacokinetics;Yanwei Wu 等;《Journal of Chromatographic Science》;第43卷;179-182 *
Quantitative Determination of Synthesized Genotoxic Impurities in Nifuroxazide Capsules by Validated Chromatographic Methods;NADA S. ABDELWAHAB 等;《JOURNAL OF AOAC INTERNATIONAL》;第101卷(第2期);1-10 *
魏伯平 等.硝呋特尔中杂质5-硝基呋喃醛二乙酸酯和5-硝基呋喃醛连氮的测定.2006,第21卷(第3期),282-283. *

Also Published As

Publication number Publication date
CN115541755A (en) 2022-12-30

Similar Documents

Publication Publication Date Title
CN111487354B (en) Method for detecting cefixime related impurities
CN111239299B (en) Method for separating and measuring palbociclib and impurities thereof
CN111060621B (en) Method for detecting cefoperazone sodium and sulbactam sodium related substances for injection
Buchanan et al. Dual-column high-performance liquid chromatographic urinary organic acid profiling
CN117805268B (en) Detection method of Martinib related substances
CN115541755B (en) Quality control method of nifuratel tablet
Husain et al. High-performance liquid chromatographic separation and determination of small amounts of process impurities of ciprofloxacin in bulk drugs and formulations
CN110865130B (en) Olopatadine hydrochloride and detection method of related substances thereof
CN113759048B (en) Inspection method of mono-tert-butyl octadecanedioate
CN113820417B (en) Method for separating and measuring piroxicam and impurities thereof
CN110095554B (en) Method for analyzing milrinone related substances by high performance liquid chromatography
CN112666282A (en) High performance liquid detection method for impurities in calcium zinc gluconate oral solution
CN107656005B (en) Method for separating and determining erlotinib hydrochloride and potential impurities
CN118010891B (en) Detection and analysis method for related substances in tofacitinib citrate sustained release tablet
CN115856141B (en) Method for separating and measuring tinib key intermediate and relevant impurities thereof by HPLC
CN114487237B (en) Detection method of 3, 5-dimethoxy methyl benzoate
CN117347533B (en) Method for detecting related substances of compound paracetamol and renin tablets for children
CN115598267B (en) Analysis method of potential genotoxic impurities of glibenclamide Ji Tezhong
CN115236255B (en) Method for detecting related substances of loxoprofen sodium
CN114609260A (en) Method for detecting lomefloxacin hydrochloride intermediate related substances
CN118209646A (en) Method for separating and detecting biological enzyme in small molecular compound
CN118706995A (en) Analysis method and application of cefdinir intermediate medium control reaction liquid
CN115266968A (en) Method for separating and measuring sugammadex sodium intermediate and impurities thereof by HPLC
CN117871727A (en) Method for detecting citrate content in linezolid glucose injection
CN114371226A (en) Method for analyzing, detecting and refining L-amino compound and related substances thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant